BlossomHill Therapeutics is developing small molecule therapeutics for unmet medical needs in oncology and autoimmune diseases. Founded by renowned drug design and development scientist, J. Jean Cui, and biotech veteran Y. Peter Li, BlossomHill is leveraging the golden age of bringing precision cancer therapy to patients with actionable mutations. Proceeds from their funding rounds will be used by BlossomHill to fund the research and development efforts and advance lead pipeline projects into clinical development. With this approach, BlossomHill will address urgent unmet medical needs through deeper science, true originality and rich experience from proven track record of successes.

BlossomHill Therapeutics

Accounts Payable Specialist

Senior Director, Medical Writing

Executive Director, Translational Medicine & Biomarker Science

BlossomHill Therapeutics Closes $100 Million Series B Financing

BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - Business Wire

 FUSED RING KRAS INHIBITORS FOR THE TREATMENT OF DISEASES 

 Blossomhill Therapeutics presents new EGFR inhibitors 

Dr. Jean Cui, President and CEO of BlossomHill Therapeutics and Dr. Peter Li, Chairman of BlossomHill Therapeutics to Receive the Committee of 100 Circle of Excellence Award for Humanity in Science & Technology - Committee of 100

 BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer 

 Indazole macrocycles and their use 

BioMed Signs BlossomHill to Office and Lab Space in Torrey Pines - Connect CRE

This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act - STAT

Today, we announced the first cohort of patients has been dosed in the Phase 1/2 SOLARA #clinicaltrial for the study of our first-in-class macrocyclic OMNI-EGFR inhibitor, BH-30643, in EGFR & HER2 mutated non-small cell lung cancer (#NSCLC).
 
Learn more about the SOLARA study, and the unique attributes and potential of BH-30643 in the press release: https://lnkd.in/gb7zhdzV
#cancer #biotech

We’re proud to announce the completion of a $100 million financing round to support us in making a leap forward and advancing our pipeline for the treatment of #cancer and #autoimmune diseases. Learn more about the news and our commitment to redefining #precisionmedicine: https://lnkd.in/euNFdMfy
 
#Financing #Biotechnology 

Blossomhill Therapeutics presents new GTPase KRAS mutant inhibitors - BioWorld Online

BlossomHill Therapeutics Closes $71M Series A Financing - GlobeNewswire

 BlossomHill Therapeutics Moving to New Headquarters 

We’re #hiring a new Senior/Executive Director, Clinical Pharmacology in San Diego County, California. Apply today or share this post with your network.

BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President

 BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President 

 Egfr inhibitors for treating disease 

BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President - GlobeNewswire

 Kras inhibitors for treating disease 

BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer - Business Wire

BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Moving to New Headquarters - San Diego Business Journal

 Blossomhill Therapeutics presents new GTPase KRAS mutant inhibitors 

With seeds from Turning Point, a new biotech blooms with $100M to take on small molecules


              This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act
            

We are thrilled to move into our new headquarters at 10255 Science Center Drive, Suite 200, San Diego, CA 92121!

Our BlossomHill leadership team is expanding with the appointments of Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President, and Ashley Preston, Ph.D., as Senior Vice President and Head of Regulatory Affairs & Quality Assurance!
 
Their leadership will be important as we advance our first two #oncology programs through #clinical studies, reinforcing our commitment to delivering innovative precision #cancer treatments to patients in need.
 
Learn more about the appointments in our press release here: https://lnkd.in/eZt8azvQ

BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President - Business Wire

BlossomHill raises $100M in bid to repeat founders’ cancer success at Turning Point

This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

 BlossomHill Therapeutics Closes $100M Series B 

 BlossomHill ready to flourish after $100 million Series B 

BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer

 INDAZOLE MACROCYCLES AND THEIR USE 

BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering - Business Wire

Our CEO, Dr. J. Jean Cui, connected with BiotechTV’s Brad Loncar following our completion of a $100 million financing to gain insight into Dr. Cui’s perspective on #precisionmedicines and how we are working to solve unmet medical needs by re-envisioning #cancer drug development.

Watch the full video here: https://bit.ly/3Isffxy

Blossomhill Therapeutics prepares and tests new tyrosine kinase inhibitors for autoimmune disease - BioWorld MedTech

We are thrilled to see our CEO, Dr. J. Jean Cui, featured in The Medicine Maker 2024 Power List! Her leadership and groundbreaking research have brought several cutting-edge medicines to patients in need. Join us in congratulating Dr. Cui on this prestigious recognition that underscores her commitment to developing medicines that make a difference in patients’ lives. More here: https://bit.ly/3Jm09K4

English

Planning to attend #AACR25? We’re looking forward to presenting our poster describing the design and discovery of BH-30643, our super-potent, reversible, mutant-selective OMNI-EGFR inhibitor, on April 29 in #Chicago.
 
Leveraging an entirely new macrocyclic scaffold, this clinical-stage EGFR inhibitor was designed to potently and selectively target a broad spectrum of #EGFR activating and resistance mutations. Read our full press release: https://lnkd.in/ezbiryFa.
 
Check out the abstract here: https://lnkd.in/e22b-N2w, and hope to see you there!
 
American Association for Cancer Research

BlossomHill Therapeutics Closes $71M Series A Financing

BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President

 Fused ring kras inhibitors for treating disease 

BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting

 Macrocyclic compounds and use as tyk2 inhibitors 

 Combination therapy involving macrocyclic indazole compounds 


                A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA).
              

BlossomHill Therapeutics Closes $100M Series B Financing

 BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President 

We are proud to share that our President and CEO Dr. J. Jean Cui was recognized as one of the 11 Asian American executives shaping the future of biopharma by the Timmerman Report. 

This accolade further underscores Jean’s outstanding leadership, vision, and unwavering dedication to advancing medical innovation for the benefit of patients. View the full list here: https://bit.ly/3VuEK8r

We’re #hiring a new Associate Director/Director, Clinical Pharmacology in San Diego County, California. Apply today or share this post with your network.

BlossomHill Therapeutics, Inc. appoints Jason Keyes as Chief Financial Officer and Executive Vice President. 

Jason Keyes is a veteran corporate executive within the #biopharmaceutical industry who brings a breadth of leadership experience in the areas of finance, strategic planning and business development. BlossomHill is thrilled to welcome Jason to our Executive Leadership Team and look forward to the contributions Jason will make to the company's efforts to bring transformational leaps forward in patient outcomes in #oncology and #autoimmune diseases.  https://lnkd.in/gzA84dFM

 Indazole containing macrocycles and their use 


              BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering
            

Blossomhill Therapeutics presents new EGFR inhibitors - BioWorld Online

We’re #hiring a new Clinical Trial Manager/Senior Clinical Trial Manager in San Diego, California. Apply today or share this post with your network.

BlossomHill Therapeutics Chief Executive Officer Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering

We’re #hiring a new Clinical Scientist/Senior Clinical Scientist in San Diego County, California. Apply today or share this post with your network.

We’re looking forward to presenting at #AACR24! Don’t miss our poster presentations featuring preclinical data from our CLK inhibitor program. See more details below and view our abstracts here: https://bit.ly/3xkGmYM and https://bit.ly/49gHCJI American Association for Cancer Research

We are thrilled to be planning our next move into this cutting-edge Torrey Pines biotech hub in #SanDiego, made possible by the team at BioMed Realty. This space will be the new home office where we will continue to pursue our mission to address unmet medical needs in #oncology and #autoimmune disorders. Stay tuned as we continue to grow our team and push the boundaries of scientific innovation to improve patient lives!

 BlossomHill secures $100m funds to advance cancer programmes 

Elima Therapeutics patents new tyrosine kinase inhibitors for idiopathic pulmonary fibrosis - BioWorld Online

BlossomHill Therapeutics

Business:

About: